

Prof.dr. Francois Pattou

Lille University

Lille, France



Professor of General Surgery, Lille University, Lille. France
Head, General and Endocrine Surgery, University Hospital, Lille. France
Director, Translational research on Diabetes,
Univ Lille, CHU Lille, Pasteur Institute Lille, Inserm UMR 1190, Lille, France
francois.pattou@univ-lille.fr

François Pattou (56 years) became professor of Surgery at the University of Lille in 2002, and head of the Department of General and Endocrine Surgery at Lille University Hospital in 2005. FP also leads an INSERM research unit devoted to the clinical development of biotherapies for treating diabetes (U1190), and a funding member of the European Genomic Institute for Diabetes (EGID).

FP's research is devoted to the surgical treatment of endocrine and metabolic diseases and focused on cell therapy for type 1 diabetes and metabolic surgery for type 2 diabetes. He has authored more than 400 papers in high profile journals, and is the principal investigator of several ongoing clinical trials in islet cell transplantation and metabolic surgery. He also coordinates Precinash a private-public consortium devoted to the study of NASH. The recipient of numerous research grants from national and international institutions (Programme d'Investissements d'Avenir, European Commission, Innovative Medicine Initiative, Agence Nationale de la Recherche, Juvenile Diabetes Research Foundation, Fondation Francophone pour la recherche sur le diabète), François Pattou has been awarded by several prizes (National Academy of Medicine, Rachmine Levine scientific achievement award, Matmut award, Fondation de la recherche Médicale).

Ten selected publications

1. **Pattou F**, Kerr-Conte J, Wild D, In vivo imaging of transplanted human beta cells with GLP1 R_c scan. *New Engl J Med* 2010;363:1989-90
2. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, Buob D, Pigeyre M, Mathurin P, **Pattou F**. [Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study](#). *Ann Surg*. 2014 Nov;260(5):893-8.
3. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. *Gastroenterology*. 2015 Aug;149(2):379-88; quiz e15-6. doi: 10.1053/j.gastro.2015.04.014. Epub 2015 Apr 25.
4. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse W, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nature Med* 2015;21(5):512-7.
5. Baud G, Daoudi M, Hubert T, Raverdy V, Pigeyre M, Hervieux E, Devienne M, Ghunaim M, Queon A, Pigny P, Klein A, Caiazzo R, **Pattou F**. Bile diversion decreases sodium dependent glucose intestinal uptake after Roux-en-Y Gastric Bypass (RYGB). *Cell Metab* 2016 23, 547–553

6. Raverdy V, Baud G, Pigeyre M, Verkindt H, Torres F, Preda C, Thuillier D, Gélé P, Vantighem MC, Caiazzo R, **Pattou F**. [Incidence and Predictive Factors of Postprandial Hyperinsulinemic Hypoglycemia After Roux-en-Y Gastric Bypass: A Five year Longitudinal Study](#). *Ann Surg* 2016;264:878-885.
7. [Vantighem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, Machuron F, Hubert T, Frimat M, Van Belle E, Hazzan M, Pigny P, Noel C, Caiazzo R, Kerr-Conte J, **Pattou F**. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study](#). *Diabetes Care*. 2019 Nov;42(11):2042-2049.
8. Vantighem MC, de Koning EJP, **Pattou F**, Rickels MR. [Advances in \$\beta\$ -cell replacement therapy for the treatment of type 1 diabetes](#). *Lancet*. 2019 Oct 5;394(10205):1274-1285.
9. Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, **Pattou F***, Mathurin P*. [Bariatric Surgery Provides Long-term Resolution of NASH and Regression of Fibrosis](#). *Gastroenterology*. 2020;159(4):1290-1301
10. Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study. Raverdy V, Cohen RV, Caiazzo R, Verkindt H, Petry TBZ, Marciniak C, Legendre B, Bauvin P, Chatelain E, Duhamel A, Drumez E, Oukhouya-Daoud N, Chetboun M, Baud G, Ahlqvist E, Wierup N, Asplund O, Laferrère B, Groop L, Pattou F. *Lancet Diabetes Endocrinol*. 2022 Mar;10(3):167-176.

Role of bariatric surgery in NAFLD